药效评价JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
期刊：The Journal of pharmacology and experimental therapeutics发表年份：2011作者：Magda F Morton; Terrance D Barrett; Jamie Freedman; Lina Li; Michele C Rizzolio; Clodagh E Prendergast; Xiaodong Wu; Veronica Moreno; Jayashree Pyati; Katherine Figueroa; Laurence Cagnon; Guy Lagaud; Luc Ver Donck; Etienne Ghoos; Brett Allison; Micha